secwatch.observer — SEC 8-K summary
======================================

Issuer:     EKSO BIONICS HOLDINGS, INC. (CHRN)
CIK:        0001549084
Form:       8-K
Filed at:   2025-07-28T23:59:59+00:00
Accession:  0001437749-25-023643
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ekso Bionics Q2 revenue falls 58% YoY to $2.1M; net loss $2.7M
--------------------------------------------------------------

- Revenue $2.1M vs $5.0M in Q2 2024, down 58% due to lower Enterprise Health device sales.
- Gross margin 40% vs 53% prior year; gross profit $0.8M vs $2.6M.
- Net loss $2.7M ($1.24/share) vs $2.4M ($1.99/share) in Q2 2024.
- Personal Health device sales grew >50% YoY in H1 2025; cash $5.2M at June 30.
- Named Bionic P&O as first Ekso Indego Personal distributor; joined NVIDIA Connect program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549084/000143774925023643/0001437749-25-023643-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549084/000143774925023643/ekso20250520_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-023643

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer